Trial · NCT06521476
Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
NCT06521476, Phase 2, Recruiting, Sanjay R Patel
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder. Trials, record NCT06521476. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06521476
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
- NCT number
- NCT06521476
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Sanjay R Patel
- Conditions
- Central Sleep Apnea Comorbid With Opioid Use
- Interventions
- Acetazolamide, Placebo
- First posted
- 2024-07-26
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Central Apnea Index (CAI) | 7 days | The number of central apneas per hour of sleep, assessed by overnight polysomnography. * It can range from 0 to undefined events per hour. * Higher values indicate more severe central sleep apnea. |
| Secondary | Low frequency / high-frequency ratio (LF/HF ratio) | 7 days | The ratio of low frequency to high frequency spectral power from heart rate variability analysis of electrocardiogram (ECG) collected during non-rapid eye movement (NREM) sleep on overnight polysomnography |
| Secondary | Apnea Hypopnea Index (AHI) | 7 days | The number of apneas plus hypopneas per hour of sleep on overnight polysomnography * It can range from 0 to undefined events per hour. * Higher values indicates severity of apneas and hypopneas. |
| Other | Overnight urinary norepinephrine levels | 7 days | Overnight urinary norepinephrine concentration normalized to urinary creatinine concentration |
| Other | Pre-ejection period | 7 days | Pre-ejection period assessed by impedance cardiography |
| Other | Pre-sleep Arousal Scale (PSAS) score | 7 days | 16-item questionnaire assessing level of nocturnal arousal * It can range from 16 to 80. * Higher scores indicate higher levels of nocturnal arousal. |
| Other | Arousal Index | 7 days | The number of cortical arousals per hour of sleep on overnight polysomnography. * It can range from 0 to undefined events per hour. * Higher values indicate more severe sleep disturbance. |
| Other | Generalized Anxiety Disorder 7 (GAD-7) score | 7 days | 7-item questionnaire assessing anxiety symptoms * It can range from 0 to 21. * Higher scores indicate more severe anxiety. |
| Other | Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance score | 7 days | t-score derived from 8-item PROMIS sleep disturbance questionnaire * Population mean is 50 and standard deviation is 10. * Higher values indicate greater levels of sleep disturbance. |
| Other | Opioid cue-induced drug craving | 7 days | The mean craving score reported after exposure to visual opioid cues relative to craving scores after viewing neutral cues. * Mean craving score ranges from 0 to 10. * Higher scores indicate higher level of drug craving. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA059465 | The impact of central sleep apnea in patients receiving medications for opioid use disorder | PATEL, SANJAY R | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | NATIONAL INSTITUTE ON DRUG ABUSE | 2023 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06521476
GET https://conductscience.org/api/trials/v1/NCT06521476/registered